Classifications: antibiotic; third-generation cephalosporin; Therapeutic: antibiotic; cephalosporin
Prototype: Cefotaxime sodium
Pregnancy Category: B
300 mg capsules; 125 mg/5 mL suspension
Broad-spectrum semisynthetic third-generation beta-lactamase cephalosporin antibiotic.
Effective against a wide variety of gram-positive and gram-negative bacteria.
Community-acquired pneumonia, acute exacerbations of chronic bronchitis, acute maxillary sinusitis, pharyngitis, tonsillitis,
uncomplicated skin infections, bacterial otitis media.
Hypersensitivity to cefdinir and other cephalosporins.
Hypersensitivity to penicillins, penicillin derivatives; renal impairment; ulcerative colitis or antibiotic-induced colitis;
bleeding disorders; GI disorders; liver or kidney disease; pregnancy (category B), lactation. Safety and efficacy in neonates
and infants <6 mo old not established.
Route & Dosage
|Community-Acquired Pneumonia, Skin Infections
Adult: PO 300 mg q12h x 10 d
Child (6 mo12 y): PO 7 mg/kg q12h x 10 d
Chronic Bronchitis, Maxillary Sinusitis, Pharyngitis, Tonsillitis
Adult: PO 600 mg q24h or 300 mg q12h x 10 d
Child (6 mo12 y): PO 14 mg/kg q24h or 7 mg/kg q12h x 10 d
- Do not give within 2 h of aluminum- or magnesium-containing antacids or iron supplements.
- Reconstitute oral suspension to 125 mg/mL by adding water (38 mL to 60 mL bottle or 63 mL to 100 mL bottle). Shake well
before each use.
- Consult physician for dosage adjustment if creatinine clearance <30 mL/min and for patients on hemodialysis.
- Store in tightly closed container. Discard after 10 d.
Adverse Effects (≥1%) GI: Diarrhea,
nausea, abdominal pain. Metabolic:
Increased GGT, increased urine protein, hematuria. CNS:
Rash, cutaneous moniliasis. Urogenital:
Vaginal moniliasis, vaginitis
Diagnostic Test Interference
False positive for ketones or glucose in urine using nitroprusside or Clinitest.
Interactions Drug: antacids
should be taken at least 2 h before or after cefdinir; probenecid
prolongs cefdinir elimination; iron
1625% bioavailability. Peak:
24 h. Distribution:
6070% protein bound; penetrates sinus tissue, blister fluid, lung tissue, middle ear fluid. Metabolism:
In urine. Half-Life:
Assessment & Drug Effects
- Determine previous hypersensitivity to cephalosporins, penicillins, and other drug allergies before therapy is initiated.
- Carefully monitor for and immediately report S&S of: hypersensitivity, superinfection, or pseudomembranous colitis (see
- Discontinue drug and notify physician if seizures associated with drug therapy occur.
Patient & Family Education
- Allow a minimum of 2 h between cefdinir and antacids containing aluminum or magnesium, or drugs containing iron.
- Immediately contact physician if a rash, diarrhea, or new infection (e.g., yeast infection) develops.
- Drug may cause false positive for urine ketones or glucose. Consult package insert.